Related references
Note: Only part of the references are listed.Genetic Basis of Extramedullary Plasmablastic Transformation of Multiple Myeloma
Ying Liu et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
TooManyCells identifies and visualizes relationships of single-cell clades
Gregory W. Schwartz et al.
NATURE METHODS (2020)
MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma
Qiang Wang et al.
BLOOD (2020)
MIF family proteins in genitourinary cancer: tumorigenic roles and therapeutic potential
Justin C. Penticuff et al.
NATURE REVIEWS UROLOGY (2019)
Evolving complexity of MIF signaling
Stanislovas S. Jankauskas et al.
CELLULAR SIGNALLING (2019)
Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients
Irit Avivi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
The immunobiology of MIF: function, genetics and prospects for precision medicine
Insoo Kang et al.
NATURE REVIEWS RHEUMATOLOGY (2019)
The role of CXCR4 in multiple myeloma: Cells' journey from bone marrow to beyond
Tomalika Rahmat Ullah
JOURNAL OF BONE ONCOLOGY (2019)
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Andrea Cossarizza et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2019)
Young female patients with multiple myeloma have low occurrence of osteolytic lesion
Danfeng Zhang et al.
BONE (2018)
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT
Nico Gagelmann et al.
HAEMATOLOGICA (2018)
SKLB-23bb, AHDAC6-Selective Inhibitor, Exhibits Superior and Broad-Spectrum Antitumor Activity via Additionally Targeting Microtubules
Fang Wang et al.
MOLECULAR CANCER THERAPEUTICS (2018)
ZFPM2-AS1, a novel IncRNA, attenuates the p53 pathway and promotes gastric carcinogenesis by stabilizing MIF
Fanyang Kong et al.
ONCOGENE (2018)
Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses
Kristen N. Balogh et al.
PLOS ONE (2018)
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT
Nico Gagelmann et al.
HAEMATOLOGICA (2018)
Macrophage Inhibitory Factor-1 (MIF-1) controls the plasticity of multiple myeloma tumor cells
Danielle Joseph et al.
PLOS ONE (2018)
CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma
Constantin Lapa et al.
THERANOSTICS (2017)
Cytogenetics in multiple myeloma patients progressing into extramedullary disease
Lenka Besse et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
MIF Is Necessary for Late-Stage Melanoma Patient MDSC Immune Suppression and Differentiation
Kavitha Yaddanapudi et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features
Leo Rasche et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
MIF Maintains the Tumorigenic Capacity of Brain Tumor-Initiating Cells by Directly Inhibiting p53
Raita Fukaya et al.
CANCER RESEARCH (2016)
Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response
Yuhuan Zheng et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Targeting MIF in Cancer: Therapeutic Strategies, Current Developments, and Future Opportunities
Ciaran O'Reilly et al.
MEDICINAL RESEARCH REVIEWS (2016)
Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses
S. J. de Haart et al.
BLOOD CANCER JOURNAL (2016)
Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response
Yuhuan Zheng et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets
Evan Z. Macosko et al.
CELL (2015)
Features of Extramedullary Disease of Multiple Myeloma: High Frequency of P53 Deletion and Poor Survival: A Retrospective Single-Center Study of 834 Cases
Shuhui Deng et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse
Ludek Pour et al.
HAEMATOLOGICA (2014)
The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells
Cole Trapnell et al.
NATURE BIOTECHNOLOGY (2014)
MIF Family Members Cooperatively Inhibit p53 Expression and Activity
Stephanie E. Brock et al.
PLOS ONE (2014)
Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor
Nina Reinart et al.
BLOOD (2013)
Cytogenetics of extramedullary manifestations in multiple myeloma
Lisa Billecke et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Control of Tumor-Associated Macrophage Alternative Activation by Macrophage Migration Inhibitory Factor
Kavitha Yaddanapudi et al.
JOURNAL OF IMMUNOLOGY (2013)
Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib
H. A. F. Stessman et al.
LEUKEMIA (2013)
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents
Saad Z. Usmani et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Role of Macrophage Migration Inhibitory Factor in the Regulatory T Cell Response of Tumor-Bearing Mice
Susanna Choi et al.
JOURNAL OF IMMUNOLOGY (2012)
Macrophage Migration Inhibitory Factor Promotes Tumor Growth and Metastasis by Inducing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kendra D. Simpson et al.
JOURNAL OF IMMUNOLOGY (2012)
Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach
Joan Blade et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma
K. Detweiler Short et al.
LEUKEMIA (2011)
Initial genome sequencing and analysis of multiple myeloma
Michael A. Chapman et al.
NATURE (2011)
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients
Annemiek Broyl et al.
BLOOD (2010)
Loss of ATM/Chk2/p53 Pathway Components Accelerates Tumor Development and Contributes to Radiation Resistance in Gliomas
Massimo Squatrito et al.
CANCER CELL (2010)
Macrophage migration inhibitory factor expression in cervical cancer
Mathias Krockenberger et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
Extravasation and homing mechanisms in multiple myeloma
Isabelle Vande Broek et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
George Mulligan et al.
BLOOD (2007)
Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma
CV Hedvat et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Share Paper
